Drug Pipeline

Expanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.

ASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies

Determining what to measure, and how best to measure it, can be surprisingly complex-and appropriate metrics can vary between cancer types and patient populations.

Studies have found that getting diabetes under control early on has immediate benefits. Here’s how providers and patients can more proactively address the disease.

Specific benefits patients with diabetes have experienced due to the ACA, and how those benefits are impacting diabetes costs.

At the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.

A value-based cancer care model focuses on better aligning providers with health plans and employers through an IPA.

Although the diabetes pipeline is not large, we continue to have progress in meeting the unmet needs of patients with diabetes.

Participants in a new CMS payment program will attempt to improve the effectiveness and efficiency of cancer care delivery. Here’s how.

Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here’s how. Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here's how.

Personalization is the key to a healthcare experience that optimizes outcomes, improves the customer experience and, ultimately, lowers costs to the healthcare system. Find out why it’s especially key for diabetic patients.

Mobile health (mHealth) offers new ways to empower patients with diabetes in caring for themselves and making decisions that support their health.

Telemedicine could improve diabetic patient outcomes, expand access, and provide better economic value for patients. Find out how.

Consequences range from cardiovascular disease to renal disease

Here are some of the innovative approaches payers and providers are taking to quell the diabetes epidemic, and curb the costs associated with it.

A successful YMCA diabetes program has prompted the Obama administration to expand Medicare to cover programs to prevent diabetes among those at high risk of developing the disease.

The sheer volume of diabetes patients has made it a big driver of medication spending. Here are some important formulary considerations.

… and solutions from experts

Rob Danoff, DO, of Aria Health System, explains what should be done to reduce health management costs, while improving care of diabetic patients.

In this Q&A, experts discuss how emerging treatments and technologies are affecting diabetes costs.

Humana is using past evidence to reach patients at risk for diabetes.

As 2016 gets underway, improvements in diabetes health management are expected to progress. Here are some of the noteworthy trends to watch.

While diabetes, particularly type 2, remains an epidemic, the number of new diagnoses has begun to slow. Here are some developments contributing to the decrease.

Broader exchange of ideas for diabetes health management and related programs may result in more efficient community-based programs with a wider impact.

Several studies have demonstrated that telemedicine programs of different types can yield the same or better results than more traditional diabetes interventions.

AML’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents

The results of a large study of the impact of empagliflozin (Jardiance) on cardiovascular outcomes were recently published. Here are some key takeaways.

An important question is whether improvements in technology can make better control accessible to patients who are not currently good candidates for insulin pumps.

For patients with diabetes or high blood cholesterol, greater medication adherence is associated with a greater likelihood that the patient will achieve target biometric A1c and low-density lipoprotein levels, respectively, according to a poster session presented at the Academy of Managed Care Pharmacy meeting.

During their session at the AMPC conference in Orlando, presenters identified several diabetes management approaches that are improving medication adherence.